IL152389A0 - Aromatase inhibitors and monoclonal anti-her1 antibodies as antitumor agents - Google Patents
Aromatase inhibitors and monoclonal anti-her1 antibodies as antitumor agentsInfo
- Publication number
- IL152389A0 IL152389A0 IL15238901A IL15238901A IL152389A0 IL 152389 A0 IL152389 A0 IL 152389A0 IL 15238901 A IL15238901 A IL 15238901A IL 15238901 A IL15238901 A IL 15238901A IL 152389 A0 IL152389 A0 IL 152389A0
- Authority
- IL
- Israel
- Prior art keywords
- monoclonal anti
- aromatase inhibitors
- antitumor agents
- her1 antibodies
- her1
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 239000003886 aromatase inhibitor Substances 0.000 title 1
- 229940046844 aromatase inhibitors Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57135500A | 2000-05-15 | 2000-05-15 | |
| PCT/EP2001/004468 WO2001087334A1 (en) | 2000-05-15 | 2001-04-19 | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL152389A0 true IL152389A0 (en) | 2003-05-29 |
Family
ID=24283360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15238901A IL152389A0 (en) | 2000-05-15 | 2001-04-19 | Aromatase inhibitors and monoclonal anti-her1 antibodies as antitumor agents |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1282440A1 (es) |
| JP (1) | JP2003533490A (es) |
| KR (1) | KR20030014223A (es) |
| CN (1) | CN1429118A (es) |
| AU (1) | AU784617B2 (es) |
| BR (1) | BR0110732A (es) |
| CA (1) | CA2409652A1 (es) |
| CZ (1) | CZ20023748A3 (es) |
| EA (1) | EA005931B1 (es) |
| EE (1) | EE200200622A (es) |
| HK (1) | HK1054200A1 (es) |
| HU (1) | HUP0301877A2 (es) |
| IL (1) | IL152389A0 (es) |
| MX (1) | MXPA02011194A (es) |
| NO (1) | NO20025302D0 (es) |
| NZ (1) | NZ523004A (es) |
| PL (1) | PL360153A1 (es) |
| SK (1) | SK16022002A3 (es) |
| WO (1) | WO2001087334A1 (es) |
| ZA (1) | ZA200209815B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| EP1282443B1 (en) | 2000-05-19 | 2009-09-02 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| ES2269682T3 (es) * | 2001-01-26 | 2007-04-01 | Pfizer Italia S.R.L. | Exemestano para tratar transtornos que dependen de hormonas. |
| GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
| AU2003218600C1 (en) | 2002-03-26 | 2009-12-17 | Zensun (Shanghai) Science & Technology Co., Ltd. | ERBB3 based methods and compositions for treating neoplasms |
| CN1678348A (zh) * | 2002-07-01 | 2005-10-05 | 萨文特医药公司 | 用于治疗性治疗的组合物和方法 |
| FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| CN101014365B (zh) * | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
| UA94899C2 (ru) | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Фиксированное дозирование антител к her |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| EP1945224B1 (en) | 2005-10-19 | 2012-05-02 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| EP2132573B1 (en) | 2007-03-02 | 2014-04-23 | Genentech, Inc. | Predicting response to a her dimerisation inhbitor based on low her3 expression |
| DK2171090T3 (da) | 2007-06-08 | 2013-06-10 | Genentech Inc | Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
| CA2761280A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| CN102892779B (zh) | 2010-02-18 | 2016-12-21 | 基因泰克公司 | 神经调节蛋白拮抗剂及其在治疗癌症中的用途 |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
| JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
| CN102068429B (zh) * | 2010-12-28 | 2011-12-14 | 西南大学 | 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法 |
| MX2014001766A (es) | 2011-08-17 | 2014-05-01 | Genentech Inc | Anticuerpos de neuregulina y sus usos. |
| WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
| CN106987620A (zh) | 2011-11-30 | 2017-07-28 | 霍夫曼-拉罗奇有限公司 | 癌症中的erbb3突变 |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック， インコーポレイテッド | Ｈｅｒ３阻害剤に関する診断及び治療 |
| US20160038490A1 (en) * | 2012-07-18 | 2016-02-11 | Angion Biomedica Corp. | Compositions and methods for treating dysproliferative diseases |
| WO2014083178A1 (en) | 2012-11-30 | 2014-06-05 | F. Hoffmann-La Roche Ag | Identification of patients in need of pd-l1 inhibitor cotherapy |
| US10064874B2 (en) | 2014-10-22 | 2018-09-04 | Havah Therapeutics Pty Ltd. | Methods of reducing mammographic breast density and/or breast cancer risk |
| AU2016343297A1 (en) | 2015-10-22 | 2018-05-10 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| CN107417791B (zh) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双特异性抗体、其制备方法及用途 |
| CN119970752A (zh) | 2019-06-03 | 2025-05-13 | 哈瓦赫治疗有限公司 | 用于递送雄激素剂和芳香酶抑制剂的药物制剂 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
-
2001
- 2001-04-19 EP EP01929585A patent/EP1282440A1/en not_active Withdrawn
- 2001-04-19 MX MXPA02011194A patent/MXPA02011194A/es not_active Application Discontinuation
- 2001-04-19 CZ CZ20023748A patent/CZ20023748A3/cs unknown
- 2001-04-19 AU AU56309/01A patent/AU784617B2/en not_active Ceased
- 2001-04-19 HU HU0301877A patent/HUP0301877A2/hu unknown
- 2001-04-19 NZ NZ523004A patent/NZ523004A/en unknown
- 2001-04-19 PL PL36015301A patent/PL360153A1/xx not_active Application Discontinuation
- 2001-04-19 KR KR1020027015223A patent/KR20030014223A/ko not_active Ceased
- 2001-04-19 SK SK1602-2002A patent/SK16022002A3/sk not_active Application Discontinuation
- 2001-04-19 JP JP2001583801A patent/JP2003533490A/ja not_active Withdrawn
- 2001-04-19 WO PCT/EP2001/004468 patent/WO2001087334A1/en not_active Ceased
- 2001-04-19 HK HK03106504.3A patent/HK1054200A1/zh unknown
- 2001-04-19 BR BR0110732-1A patent/BR0110732A/pt not_active IP Right Cessation
- 2001-04-19 EE EEP200200622A patent/EE200200622A/xx unknown
- 2001-04-19 CA CA002409652A patent/CA2409652A1/en not_active Abandoned
- 2001-04-19 EA EA200201213A patent/EA005931B1/ru not_active IP Right Cessation
- 2001-04-19 IL IL15238901A patent/IL152389A0/xx unknown
- 2001-04-19 CN CN01809581A patent/CN1429118A/zh active Pending
-
2002
- 2002-11-05 NO NO20025302A patent/NO20025302D0/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209815A patent/ZA200209815B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK16022002A3 (sk) | 2003-04-01 |
| NO20025302L (no) | 2002-11-05 |
| HUP0301877A2 (hu) | 2003-09-29 |
| CN1429118A (zh) | 2003-07-09 |
| CZ20023748A3 (cs) | 2003-04-16 |
| EA200201213A1 (ru) | 2003-04-24 |
| AU5630901A (en) | 2001-11-26 |
| PL360153A1 (en) | 2004-09-06 |
| ZA200209815B (en) | 2003-12-03 |
| WO2001087334A1 (en) | 2001-11-22 |
| EP1282440A1 (en) | 2003-02-12 |
| EA005931B1 (ru) | 2005-08-25 |
| KR20030014223A (ko) | 2003-02-15 |
| JP2003533490A (ja) | 2003-11-11 |
| BR0110732A (pt) | 2003-02-04 |
| AU784617B2 (en) | 2006-05-18 |
| HK1054200A1 (zh) | 2003-11-21 |
| EE200200622A (et) | 2004-06-15 |
| NZ523004A (en) | 2004-09-24 |
| CA2409652A1 (en) | 2001-11-22 |
| MXPA02011194A (es) | 2003-03-10 |
| NO20025302D0 (no) | 2002-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL152389A0 (en) | Aromatase inhibitors and monoclonal anti-her1 antibodies as antitumor agents | |
| IL158643A (en) | Anti-hmg monoclonal antibodies and compositions containing the same | |
| HUP0300841A3 (en) | Agonist anti-trk-c monoclonal antibodies | |
| GB0029360D0 (en) | Humanised antibodies and uses thereof | |
| IL149701A0 (en) | Use of anti-ctla-4 antibodies | |
| IL156030A0 (en) | Humanized antibodies | |
| AU1174702A (en) | Humanized anti-lt-beta-r antibodies | |
| EP1432444A4 (en) | ANTI-BETA ANTIBODIES | |
| EP1071458A4 (en) | HUMANIZED ANTIBODIES AND CORRESPONDING USES THEREOF | |
| AU1091802A (en) | Degraded agonist antibody | |
| IL164021A0 (en) | Antibodies and anti-pharmaceutical compositions containing the same | |
| AU2002340167A8 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
| EP1331567A4 (en) | CREATION METHOD AND METHOD OF DELETING SHEET MUSIC | |
| AU2002365649A8 (en) | Anti-dota antibody | |
| IL154000A0 (en) | Use of antibodies against specific mhc-peptide complexes | |
| AU2001290315A1 (en) | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding | |
| AU5441000A (en) | Human monoclonal antibody | |
| PL359865A1 (en) | Peptide deformylase inhibitors | |
| IL158395A0 (en) | Aromatase inhibitor for use in reproduction | |
| IL151884A0 (en) | Peptide deformylase inhibitors | |
| EP1446416A4 (en) | TUMOR-SPECIFIC MONOCLONAL ANTIBODIES | |
| GB0029846D0 (en) | Monoclonal antibody | |
| GB0030139D0 (en) | Monoclonal antibody | |
| GB0003359D0 (en) | Monoclonal antibodies | |
| GB0008160D0 (en) | Monoclonal antibodies |